During the recent International Conference on Alzheimer's Disease and Related Disorders (ICAD), IOS Press was honored to present Queen Sofia of Spain with a commemorative edition of Alzheimer's Disease: A Century of Scientific and Clinical Research. This landmark work commemorates the centennial of Alois Alzheimer's discovery of what would be known as Alzheimer's Disease (AD). Each conference participant received a copy of the book with the compliments of GlaxoSmithKline.
Khalid Iqbal, one of the conveners of the conference, makes the presentation to Queen Sofia. Left to right are George Perry, Queen Sofia, Khalid Iqbal, Elena Salgado, Spanish Minister of Health, and Jesús Avila.
Through her Queen Sofia Foundation, the Alzheimer's Project, a care and research facility being built in Madrid, will provide inpatient, outpatient, and family services for families that have to deal with Alzheimer's Disease. The book traces how the true importance of AD as the major cause of late life dementia ultimately came to light and narrates the evolution of the concepts related to AD throughout the years and its recognition as a major public health problem, with an estimated 30-40 million people affected by AD today. This milestone work has been guided by four of the most prominent voices in the field today, George Perry, Dean of the University of Texas at San Antonio College of Sciences and Professor of Pathology and Neurosciences, Case Western Reserve University, Editor-in-Chief, Journal of Alzheimer's Disease; Jesús Avila, Center for Molecular Biology, University Autónoma of Madrid, Senior Editor, Journal of Alzheimer's Disease; June Kinoshita, Executive Editor, Alzheimer Research Forum; and Mark A. Smith, Department of Pathology, Case Western Reserve University, Co-Editor-in-Chief, Journal of Alzheimer's Disease.
George Perry commented, "The book brings to life, and in many instances revisits and reflects on, the classic studies that have essentially defined Alzheimer's disease research. My co-editors and I are extremely pleased that this project has attracted participation from nearly every single player in the field and, having read each contribution and now received feedback from readers, I am convinced that the book is destined to become one of the defining works in the field."
According to Dr. Perry, "These writings bring to the practitioner, student and interested lay person a perspective not only on the past, but also on where the Alzheimer's disease field is likely to go in the future. Only time will tell whether these milestones have charted the future accurately, but they are unquestionably the foundation upon which the future will be built."
Contact a.engelen@iospress.nl or market@iospress.nl for additional information or to schedule an interview. Visit http://www.alzheimer100.com to view the table of contents including abstracts of each article.
About the Journal of Alzheimer's Disease
The Journal of Alzheimer's Disease (www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer's disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer's disease.
About IOS Press
Commencing its publishing activities in 1987, IOS Press (www.iospress.com) is a rapidly expanding scientific, technical, medical and professional publishing house focusing on a broad range of subject areas. Headquartered in Amsterdam, IOS Press publishes approximately 200 new books each year, including Delft University Press titles, and 70 international journals, covering topics ranging from computer science and mathematics to medicine and the natural sciences. Electronic access to all journals is now available. IOS Press also maintains offices in the Washington, DC area and Berlin and a co-publishing relationship with Ohmsha, Ltd (Tokyo).